United Therapeutics Corp
UTHR
$587.50
+0.46%
United Therapeutics Corp is a commercial-stage biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH), a rare, progressive disease characterized by abnormally high blood pressure in the lungs' arteries. Its portfolio is anchored in the prostacyclin pathway, with most products built around the molecule treprostinil, marketed as Tyvaso DPI (inhalation powder), Remodulin (injection), Orenitram (extended-release tablets), plus Adcirca and Unituxin; Tyvaso DPI is the largest revenue contributor and the U.S. accounts for the vast majority of sales. The company occupies a leadership position in PAH with a deeply entrenched, high-margin franchise, but it faces intensifying competition from Liquidia's Yutrepia and Insmed, making the durability of its treprostinil moat a central investor debate. The current narrative is defined by a recent patent victory that reduced near-term competitive threats, FDA acceptance of the ralinepag NDA (a next-generation IP receptor agonist), and positive Phase 3 Tyvaso data in a new lung disease indication that could materially expand the addressable market, even as some analysts flag declining earnings estimates and a cautious stance on the sustainability of the recent rally.…
UTHR
United Therapeutics Corp
$587.50
Related headlines
UTHR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $661.29 and implied upside of +12.6% versus the current price.
Average Target
$661.29
0 analysts
Implied Upside
+12.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$368 - $728
Analyst target range
Coverage is solid with 14 analysts, and the consensus is bullish: the recommendation is "buy" with a mean rating of 1.87 (on a 1-to-5 scale where 1 is Strong Buy), and the average target price of $656.93 implies roughly +23.2% upside from the current $533.12. The consensus leans clearly bullish, supported by recent institutional actions including RBC Capital reiterating Outperform (August 6, 2026), JP Morgan maintaining Overweight (July 23, 2026), and Wells Fargo upgrading to Overweight from Equal Weight (May 7, 2026), though B of A Securities and Morgan Stanley remain Neutral/Equal Weight, reflecting a split between bulls and cautious holds. The target range is wide, from a low of $368.00 to a high of $728.00, a spread of roughly 98% of the current price that signals meaningful disagreement about the franchise's trajectory. The high target of $728.00 implies roughly +36.6% upside and likely assumes successful ralinepag commercialization, expansion of Tyvaso into new indications, and multiple expansion as competitive fears fade, while the low target of $368.00 implies about -31.0% downside and prices in margin compression and share loss to Yutrepia. The wide spread, combined with the estimated EPS range of $43.19 to $62.46 (average $53.14) and revenue range of $5.05 billion to $6.69 billion (average $5.89 billion), underscores high uncertainty around the competitive and pipeline outcome; the consensus average EPS of $53.14 against the current price implies a forward PE near 10x, which is unusually cheap and suggests the market is discounting the analysts' more optimistic scenarios.
Bulls vs Bears: UTHR Investment Factors
The bull case rests on hard numbers: 87.3% gross margins, $1.09 billion in TTM free cash flow, a debt-free balance sheet, and a 16.17x trailing PE that sits in the lower-middle of UTHR's own historical 8.75x-24.14x band, all against an analyst average target of $656.93 (+23.2%). The bear case is equally concrete: revenue declined 1.92% year-over-year, the trailing four quarters are flat below the $799.5 million Q3 2025 peak, and roughly 58% of sales come from a single product facing direct generic-style competition from Yutrepia. On balance the evidence slightly favors the bulls because the downside is already substantially priced into a mid-teens multiple while the pipeline catalysts (ralinepag NDA acceptance, new Tyvaso indication) are not, but the margin of comfort is thin. The single most important tension is whether Tyvaso revenue holds above roughly $450 million per quarter as Yutrepia ramps; if it does, the cheap multiple re-rates toward the $657 consensus, and if it does not, the 15.78x forward PE proves to be a value trap rather than a discount.
Bullish
- Fortress balance sheet, near-zero debt: Debt-to-equity is just 0.0053, the current ratio is 6.60, and cash stood at $1.80 billion at Q2 2026. With $1.09 billion of trailing free cash flow and interest coverage above 100x, UTHR can self-fund R&D, ralinepag launch costs, and buybacks without dilution or financing risk.
- Elite margins at a discount multiple: Q2 2026 gross margin was 87.3%, operating margin 47.7%, and net margin 42.5%, yet the stock trades at only 16.17x trailing and 15.78x forward earnings. An 11.03x EV/EBITDA for a business generating $1.09 billion in TTM free cash flow implies the market is pricing in franchise erosion that has not yet appeared in the numbers.
- Analyst consensus implies 23% upside: 14 analysts carry a 'buy' consensus with a mean rating of 1.87 and an average target of $656.93, roughly +23.2% from $533.12. Recent actions lean constructive, including RBC reiterating Outperform (Aug 6, 2026), JP Morgan maintaining Overweight (Jul 23, 2026), and Wells Fargo upgrading to Overweight (May 7, 2026).
- Pipeline catalysts de-risk the franchise: The October 1 patent victory sent shares up 12.6% in a single session and reduced near-term Yutrepia competition, while the FDA accepted the ralinepag NDA (Aug 28, 2026) and positive Phase 3 Tyvaso data in a new lung disease indication (Mar 30, 2026) open a materially larger addressable market beyond the current $452.6 million Tyvaso base.
Bearish
- Revenue is flat to declining: Q2 2026 revenue of $783.3 million fell 1.92% year-over-year versus $798.6 million, and the trailing four quarters ($783.3M, $781.5M, $790.2M, $799.5M) show a plateau below the Q3 2025 peak. A 15.78x forward PE against a shrinking top line offers no growth cushion if the decline steepens.
- Extreme concentration in Tyvaso: Tyvaso at $452.6 million is roughly 58% of quarterly revenue, with Remodulin ($126.3M) and Orenitram ($125.7M) also treprostinil-based, meaning nearly the entire franchise depends on one molecule. Liquidia's Yutrepia and Insmed competition target exactly this pathway, so any share loss hits the core of the investment case.
- Earnings estimates trending down: Zacks flagged declining earnings estimates alongside a Hold rating after the October rally, and the forward PE of 15.78x versus trailing 16.17x implies the market expects roughly flat earnings. Rising R&D ($146.3M in Q2 2026 versus $134.0M a year earlier) pressures near-term EPS if revenue does not reaccelerate.
- Intermediate trend still damaged: Despite the +6.95% one-month bounce, the stock is down 9.39% over six months and 0.48% over three months, with relative strength of -16.87 versus SPY over six months. At $533.12 the stock sits 12.5% below its $609.35 high, and the October spike to $571.38 has already faded back toward $533.
UTHR Technical Analysis
UTHR is in a choppy, range-bound consolidation rather than a clean trend: the stock is up 23.21% over the past year but sits at $533.12, which is roughly 62.2% of its 52-week range of $409.07 to $609.35, meaning it is neither at momentum-driven highs nor at capitulation lows. The 1-year gain of 23.21% versus the S&P 500's 15.53% (relative strength of +7.68) confirms modest long-term outperformance, but the price is still about 12.5% below the 52-week high, suggesting the market has not fully re-rated the name despite the positive fundamental headlines. The stock's positioning in the middle-upper portion of its range implies a market that is constructive but unconvinced, leaving room for a breakout if catalysts materialize. Recent momentum is improving but remains fragile: the 1-month change of +6.95% sharply outpaces the 3-month change of -0.48% and the 6-month change of -9.39%, a pattern of deceleration followed by a sharp mean-reversion bounce. This 1-month surge (relative strength of +5.73 versus SPY's +1.22%) was driven by the October 1 patent victory that sent shares up 12.6% in a single session, but the 3-month relative strength of -3.17 and 6-month relative strength of -16.87 reveal that the intermediate trend is still repairing damage from a summer downtrend that took the stock from roughly $596 in early May to a low near $472 in late September. The divergence between the strong 1-month bounce and the negative 3- and 6-month trends signals a potential trend reversal in its early stages rather than a confirmed new uptrend, and the absence of RSI data limits confirmation of whether the bounce is overbought. Key levels are well defined: support sits at the 52-week low of $409.07, with a nearer psychological floor around the September low of $472.21, while resistance is the 52-week high of $609.35, with the $570-$596 zone (the May/October spike highs) acting as an intermediate ceiling. A breakout above $609.35 would confirm a new leg higher and validate the patent and pipeline catalysts, whereas a breakdown below $472 would signal that the October rally was a failed spike and reopen the path toward the $409 low. The beta of 0.49 is a critical risk-management input: UTHR is roughly half as volatile as the market, meaning its 20.87% max drawdown occurred with far less market-driven beta and more idiosyncratic (patent/litigation/clinical) risk, so position sizing should account for event risk rather than broad market swings. Volume of 668,237 shares on the latest session is modest and should be monitored for confirmation on any breakout.
Beta
0.49
0.49x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$409-$609
Price range past year
Annual Return
+37.8%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | +20.0% | -1.0% |
| 3m | +11.2% | +2.9% |
| 6m | +3.6% | +6.5% |
| 1y | +37.8% | +13.1% |
| ytd | +18.3% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue is essentially plateauing at a high level rather than growing: Q2 2026 revenue of $783.3 million declined 1.92% year-over-year versus Q2 2025's $798.6 million, and the trailing four quarters ($783.3M, $781.5M, $790.2M, $799.5M) show a flat-to-slightly-declining trajectory from the $799.5M peak in Q3 2025. Segment data reveals the concentration risk: Tyvaso at $452.6 million is the dominant driver, followed by Remodulin at $126.3 million and Orenitram at $125.7 million, while Adcirca ($6.7M) and Unituxin ($65.2M) are immaterial, meaning the entire investment case hinges on defending and extending the Tyvaso franchise against Yutrepia. The flat revenue trend, combined with the ralinepag NDA acceptance and new Tyvaso indication data, frames the debate as one of whether pipeline expansion can reaccelerate growth before competitive erosion sets in. Profitability remains exceptional: Q2 2026 net income was $333.0 million on a 42.5% net margin, with gross margin of 87.3% and operating margin of 47.7%, and the trailing net margin of 41.9% and gross margin of 87.9% are elite even by biotechnology standards. Margins have been remarkably stable, with gross margin oscillating narrowly between 82.9% (Q1 2026) and 89.0% (Q2 2025), though the Q1 2026 dip to 82.9% and net margin of 35.2% shows some quarterly volatility tied to cost of revenue ($133.4M in Q1 versus $99.5M in Q2). The key watch item is R&D, which rose to $146.3 million in Q2 2026 from $134.0 million a year earlier, a necessary investment to defend the franchise but one that pressures near-term earnings if revenue stays flat. The balance sheet is fortress-like: debt-to-equity is just 0.0053 (essentially debt-free), the current ratio is 6.60, and cash stood at $1.80 billion at Q2 2026, giving the company ample liquidity to fund R&D and buybacks internally. Free cash flow is robust at $1.09 billion TTM, and the company demonstrated capital-return discipline with $1.5 billion of stock repurchased in Q1 2026 and $58.8 million in Q2, funded entirely from operations and cash. ROE of 18.8% and ROA of 11.6% confirm high-quality capital efficiency, and with interest coverage above 100x and a cash conversion cycle that is deeply negative, financial risk is minimal; the primary risk is commercial (competitive erosion), not balance-sheet related.
Quarterly Revenue
$783300000.0B
2026-06
Revenue YoY Growth
-1.9%
YoY Comparison
Gross Margin
87.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Because net income is strongly positive ($333.0 million in Q2 2026 alone), the PE ratio is the appropriate primary metric, and UTHR trades at a trailing PE of 16.17x against a forward PE of 15.78x, a narrow gap that implies the market is pricing in only modest earnings growth rather than a reacceleration. The trailing PE of 16.17x is strikingly low for a company with 42% net margins and 87% gross margins, and the PEG ratio of 1.16 suggests the valuation is roughly in line with growth expectations, while the EV/EBITDA of 11.03x and PS of 6.78x round out a picture of a cheap, cash-generative franchise. The forward PE of 15.78x versus trailing 16.17x implies the market expects earnings to be roughly flat, consistent with the -1.92% revenue decline and the competitive overhang. Peer comparison is constrained by the absence of explicit industry-average multiples in the provided valuation data, but contextually UTHR's 16.17x trailing PE and 6.78x PS sit at a discount to the premium multiples typically awarded to high-margin, patent-protected specialty pharma, and the 11.03x EV/EBITDA is modest for a business with 47.7% operating margins. The discount appears to reflect the market's concern about Yutrepia competition and flat revenue rather than any deficiency in profitability, suggesting the premium/discount debate hinges entirely on franchise durability. Historically, UTHR's PE has ranged from roughly 8.75x (Q1 2024) to 24.14x (Q4 2022), with recent readings of 17.32x (Q2 2026), 23.46x (Q1 2026), and 14.57x (Q4 2025), placing the current 16.17x in the lower-middle of its own multi-year band. The PS ratio of 6.78x is well below the historical range of roughly 15.8x to 33.0x seen across 2024-2026, though that historical PS series appears distorted by share-count or data conventions, so the PE comparison is more reliable. The takeaway is that the stock is not priced for optimism; it trades near the lower end of its historical PE band, implying either a value opportunity if pipeline catalysts (ralinepag, new Tyvaso indication) reaccelerate growth, or a value trap if competitive erosion continues.
PE
16.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 9x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risk centers on revenue concentration and stagnation rather than leverage. Tyvaso generated $452.6 million of Q2 2026's $783.3 million, and total revenue declined 1.92% year-over-year with the trailing four quarters flat below the $799.5 million Q3 2025 peak, so a mid-single-digit share loss to Yutrepia could turn flat into a meaningful decline. R&D rose to $146.3 million in Q2 2026 from $134.0 million a year earlier, and Q1 2026 gross margin dipped to 82.9% with net margin at 35.2% versus 42.5% in Q2, showing quarterly earnings volatility even before competitive pressure intensifies. The offsetting strength is a debt-to-equity of 0.0053, a 6.60 current ratio, $1.80 billion of cash, and $1.09 billion of TTM free cash flow, which means the risk is commercial erosion, not solvency.
Market and competitive risk is dominated by valuation compression and the PAH competitive landscape. At 16.17x trailing and 15.78x forward earnings, UTHR already trades at a discount to premium specialty pharma multiples, so the risk is less multiple contraction than earnings disappointment; the PEG of 1.16 leaves little room for negative revisions, and Zacks has already flagged declining earnings estimates. Liquidia's Yutrepia and Insmed are actively competing in the same prostacyclin pathway, and the August 31, 2026 coverage of Yutrepia's momentum underscores that the competitive threat is live despite the October 1 patent victory. Beta of 0.49 limits broad-market sensitivity, but that also means idiosyncratic events, such as an adverse litigation ruling or a ralinepag regulatory setback, drive the stock far more than macro rotation.
In a worst-case scenario, Yutrepia gains formulary access faster than expected, Tyvaso revenue slips below $400 million per quarter, ralinepag launch is delayed or priced below expectations, and the market re-rates the stock toward the low end of its historical PE band. The analyst low target of $368.00 implies roughly -31.0% from $533.12, and the 52-week low of $409.07 implies about -23.3%; a break below the September low of $472.21 would likely open the path toward that $409 level. Given the -20.87% max drawdown already experienced, an investor should size positions assuming a realistic 25-30% downside in an adverse competitive outcome, with the $368 bear target as the tail-risk floor.